Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Exosome-Derived Biomarker Predicts Likelihood of Developing Alzheimer's Disease

By LabMedica International staff writers
Posted on 18 Jul 2016
Neurological disease researchers have developed a method for using a biomarker in the blood to predict the likelihood of mild cognitive impairment (MCI) progressing into full-blown Alzheimer's disease (AD).

"MCI is often a transitional stage between normal aging and dementia," said senior author Dr. More...
Robert A. Rissman, associate professor of neurosciences at the University of California, San Diego (USA). "It is associated with more minor cognitive impairment and carries an increased risk of developing Alzheimer's dementia."

The method depends on quantifying levels of AD-related proteins in plasma neuronal derived exosomes (NDEs). Exosomes are cell-derived vesicles that are present in many and perhaps all biological fluids, including blood, urine, and cultured medium of cell cultures. The reported diameter of exosomes is between 30 and 100 nanometers, which is larger than low-density lipoproteins but much smaller than red blood cells. Exosomes, which contain RNA, proteins, lipids and metabolites that are reflective of the cell type of origin, are either released from the cell when multivesicular bodies fuse with the plasma membrane, or they are released directly from the plasma membrane. Exosomes have specialized functions and play a key role in coagulation, intercellular signaling, and waste management. Consequently, there is a growing interest in the clinical applications of exosomes for prognosis, therapy, and as biomarkers for health and disease.

For the current study, plasma exosomes were extracted, precipitated, and enriched for neuronal source by precipitation with antibodies specific for the neuronal cell adhesion molecule L1CAM. NDEs were characterized by size and shape, and extracted NDE protein biomarkers were quantified by ELISAs. In some experiments, the content of plasma NDEs was injected into normal mice, and results were characterized by immunohistochemistry to determine pathogenic potential.

Results published in the May 7, 2016, online edition of the journal Alzheimer's & Dementia revealed that plasma NDE levels of the proteins P-T181-tau, P-S396-tau, and Abeta1–42 were significantly higher, whereas those of neurogranin (NRGN) and the repressor element 1-silencing transcription factor (REST) were significantly lower in AD and MCI converting to AD (ADC) patients compared to cognitively normal controls (CNC) subjects and stable MCI patients.

Mice injected with plasma NDEs from ADC patients displayed increased P-tau (PHF-1 antibody)–positive cells in the CA1 region of the hippocampus compared to mice injected with plasma NDEs from CNC or stable MCI patients.

"The fact that these NDEs could induce pathological-like structures in naïve mice suggests that the contents of NDEs are bioactive," said Dr. Rissman. "It also suggests that released NDEs can be taken up by cells, raising the possibility of NDEs potential for drug delivery."

Related Links:
University of California, San Diego


New
Gold Member
Collection and Transport System
PurSafe Plus®
Portable Electronic Pipette
Mini 96
New
Urine Chemistry Control
Dropper Urine Chemistry Control
New
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.